Prescribers' satisfaction with delivering medications for opioid use disorder.
BACKGROUND
Expanding access to medications for opioid use disorder (MOUD), such as buprenorphine and extended release (XR) naltrexone, is critical to addressing the US opioid epidemic, but little is known about prescriber satisfaction with delivering these two types of MOUD. The current study describes the satisfaction of prescribers delivering buprenorphine and XR-naltrexone while examining whether satisfaction is associated with current patient census and organizational environment.


METHODS
As part of a cluster randomized clinical trial (RCT) focused on expanding access to medication for opioid use disorder, 41 MOUD prescribers in Florida, Ohio, and Wisconsin completed a web-based survey. The survey included measures of prescriber satisfaction with delivering buprenorphine treatment and XR-naltrexone. In addition, the survey measured several prescriber characteristics and their perceptions of the organizational environment.


RESULTS
Prescribers were generally satisfied with their work in delivering these two types of MOUD. Prescribers reporting a greater number of patients (r = .46, p = .006), those who would recommend the center to others (r = .56, p < .001), and those reporting positive relationships with staff (r = .56, p < .001) reported significantly greater overall satisfaction with delivering buprenorphine treatment. Prescribers who more strongly endorsed feeling overburdened reported lower overall buprenorphine satisfaction (r = -.37, p = .02). None of the prescriber characteristics or perceptions of the organizational environment were significantly associated with overall satisfaction with delivering XR-naltrexone treatment.


CONCLUSIONS
The generally high levels of satisfaction with both types of MOUD is notable given that prescriber dissatisfaction can lead to turnover and impact intentions to leave the profession. Future research should continue to explore the prescriber characteristics and organizational factors associated with satisfaction in providing different types of MOUD.


REGISTRATION
ClinicalTrials.gov. NCT02926482. Date of registration: September 9, 2016. https://clinicaltrials.gov/ct2/show/NCT02926482 .
['Knudsen|Hannah K|HK|', 'Brown|Randy|R|', 'Jacobson|Nora|N|', 'Horst|Julie|J|', 'Kim|Jee-Seon|JS|', 'Kim|Hanna|H|', 'Madden|Lynn M|LM|', 'Haram|Eric|E|', 'Molfenter|Todd|T|']
D000701:Analgesics, Opioid D002047:Buprenorphine D006801:Humans D009271:Naltrexone D009292:Narcotic Antagonists D009293:Opioid-Related Disorders D010549:Personal Satisfaction
opioid use disorder buprenorphine prescriber satisfaction extended-release naltrexone